-
Sector Analysis
Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) – Epidemiology Forecast to 2030
Diagnosed prevalent cases of chronic kidney disease (CKD) in the seven major markets (7MM*) combined is expected to increase from 8.57 million cases in 2020 to 9.44 million in 2030, at an annual growth rate (AGR) of 1.02%, according to GlobalData, a leading data and analytics company. Of the 7MM, the diagnosed prevalent cases of CKD in the US are expected to increase at an AGR of 1.59% between 2020Â and 2030, followed by Spain (1.51%), and France (1.19%). The major...
-
Sector Analysis
Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) – Global Drug Forecast and Market Analysis to 2030
CKD is a chronic condition in which patients suffer from an irreversible and progressive loss in renal function over many months or years, ultimately resulting in end-stage renal disease and the requirement for renal replacement therapy. CKD manifests when both kidneys are damaged sufficiently to hinder the removal of metabolic products from the body and the ability to provide mineral balance. The Centers for Disease Control and Prevention states that approximately 96% of people with kidney damage or mild to...
-
Sector Analysis
OpportunityAnalyzer: Late – Stage Chronic Kidney Disease – Opportunity Analysis and Forecasts to 2026
The late-stage chronic kidney disease (CKD) - Induced Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia market is expected to undergo significant growth over the next ten years across the seven major markets (7MM) covered in this report (US, France, Germany, Italy, Spain, UK, and Japan). The main driver of this expansion will be the dramatic increase in disease prevalence. According to primary research, GlobalData has determined that there is a high level of unmet need remaining for CKD patients. Despite the launch of...